FDA Accepts Resubmission of New Drug Application for Duobrii Lotion.
M2 PHARMA-August 30, 2018-FDA Accepts Resubmission of New Drug Application for Duobrii Lotion
(C)2018 M2 COMMUNICATIONS
- The US Food and Drug Administration has accepted the resubmitted New Drug Application for Duobrii (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis, prescription dermatology health care businesses Ortho Dermatologics said.
The FDA accepted the application as a Class 2 resubmission, with a PDUFA action date of February 15, 2019.
If approved, Duobrii will be the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation for the treatment of plaque psoriasis in adult patients, allowing for a potentially expanded duration of use.
About Ortho Dermatologics
Ortho Dermatologics, a Bausch Health company, is one of the largest prescription dermatology businesses in the world dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses.
The Ortho Dermatologics portfolio includes several leading acne, anti-fungal and anti-infective products.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 30, 2018|
|Previous Article:||KinoPharma , National Institutes for Quantum and Radiological Science and Technology Launch Collaborative Research Project for Exploring New Drug...|
|Next Article:||GSK granted licence extension for Nucala in Europe.|